The SARM1 targeting therapeutics market is projected to grow at a CAGR of 102.1%, during the period 2033-2040

5
health-fitness

Summary

SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share

Press Release

Amazon Music Disney Promo

Roots Analysis has announced the addition of “SARM1 Inhibitors Therapeutics Market, 2022 – 2040” report to its list of offerings.

 

Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders across various preclinical studies and early stages of clinical development, worldwide. With the ongoing pace of innovation in this field, increasing R&D activity and promising pre-clinical data, several promising leads are anticipated to be commercially launched over the coming decade and SARM1 targeting therapeutics market is anticipated to witness substantial growth in the mid to long-term.

 

Key Market Insights

 

Presently, several SARM1 targeting therapy candidates are being developed by various industry players

About 65% of the pipeline candidates are currently being evaluated in the preclinical stages of development, followed by those currently in the discovery stage (35%). Further, it is worth mentioning that close to 85% of the SARM1 inhibitors are small molecules.

 

Currently, a number of companies claim to be engaged in the development of SARM1 inhibitors

The SARM1 inhibitors market is dominated by the presence of large companies (81%), followed by small players (19%). In addition, around 20% of the players were established post-2010.

 

120+ articles related to SARM1 inhibitors have been published between 2011 and 2022

Majority (81%) of the articles published in this domain were research papers, followed by review papers (12%). It is important to note that more than 70% of the total number of articles were published post-2018.

 

Over 30 grants have been awarded for research related to SARM1 inhibitors, since 2014

Close to 40% of the total amount was awarded under the R01 mechanism (which supports research projects). Further, genetics and neurology emerged as the key research departments, having received 34% of the total grants, each.

 

 

 

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/sarm1-inhibitors-market/request-sample.html

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/sarm1-inhibitors-market.html

or email [email protected]

 

You may also be interested in the following titles:

  1. RNAi Market: Therapeutics and Technologies (Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition): Industry Trends and Global Forecasts, 2022-2035
  2. Global Therapeutic Vaccines Market: Industry Trends and Global Forecasts, 2022-2035

 

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

 

Contact:

Ben Johnson

+1 (415) 800 3415

[email protected]